

DAFTAR PUSTAKA

- Abdellatif, M. M., Khalil, I. A., Elakkad, Y. E., Eliwa, H. A., Samir, T. M., & Al-Mokaddem, A. K. (2020). Formulation and characterization of sertaconazole nitrate mucoadhesive liposomes for vaginal candidiasis. *International Journal of Nanomedicine*, *15*, 4079–4090. <https://doi.org/10.2147/IJN.S250960>
- Akhtar, S., Masood, S., Tabassum, S., & Rizvi, D. A. (2012). Efficacy of itraconazole versus fluconazole in vaginal candidiasis. *Journal of the Pakistan Medical Association*, *62*(10).
- Andreani, T., Miziara, L., Lorenzón, E. N., de Souza, A. L. R., Kiill, C. P., Fanguero, J. F., Garcia, M. L., Gremião, P. D., Silva, A. M., & Souto, E. B. (2015). Effect of mucoadhesive polymers on the in vitro performance of insulin-loaded silica nanoparticles: Interactions with mucin and biomembrane models. *European Journal of Pharmaceutics and Biopharmaceutics*, *93*, 118–126. <https://doi.org/10.1016/j.ejpb.2015.03.027>
- Angga Cipta N. (2012). Peningkatan kelarutan ketokonazol Dengan teknik dispersi padat menggunakan eudragit® E100. *J. Trop. Pharm. Chem.*, *Vol 2*(1).
- Atit Tajmiati. (2017). Review Article: Vulvitis and Vaginitis in the Child Population . *Actual Research Science Academic*, *2*.
- Badan POM RI. (2105). *Bab 7 Obstetrik Ginekologi Dan Saluran Kemih*. Pusat Informasi Obat Nasional.
- Bagavatula, H., Lankalapalli, S., Tenneti, V. V. K., Beeraka, N. M. R., & Bulusu, B. T. (2014). Comparative Studies on Solubility and Dissolution Enhancement of Different Itraconazole Salts and Their Complexes. *Advances in Pharmacology and Pharmacy*, *2*(6), 85–95. <https://doi.org/10.13189/app.2014.020601>
- Bailey, E. M., Krakovsky, D. J., & Rybak, M. J. (1990). The Triazole Antifungal Agents: A Review of Itraconazole and Fluconazole. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, *10*(2), 146–153. <https://doi.org/10.1002/j.1875-9114.1990.tb02561.x>
- Baraggino, E., Orsetti, G., Ribaric, G., Wiesenfeld, V., & Pecorari, D. (1991). [Preliminary clinical study of the use of itraconazole in the treatment of vulvovaginal candidiasis]. *Minerva Ginecologica*, *43*(12), 601–604.
- Bitew, A., & Abebaw, Y. (2018). Vulvovaginal candidiasis: Species distribution of *Candida* and their antifungal susceptibility pattern. *BMC Women's Health*, *18*(1), 1–10. <https://doi.org/10.1186/s12905-018-0607-z>
- Botros, S. R., Hussein, A. K., & Mansour, H. F. (2020). A Novel Nanoemulsion Intermediate Gel as a Promising Approach for Delivery of Itraconazole: Design, In Vitro and Ex Vivo Appraisal. *AAPS PharmSciTech*, *21*(7), 12–14. <https://doi.org/10.1208/s12249-020-01830-w>

- Casari, E., Ferrario, A., Morengi, E., & Montanelli, A. (2010). Gardnerella, Trichomonas vaginalis, Candida, Chlamydia trachomatis, Mycoplasma hominis and Ureaplasma urealyticum in the genital discharge of symptomatic fertile and asymptomatic infertile women. *The New Microbiologica*, 33(1), 69–76.
- Cassone, A. (2015). Vulvovaginal Candida albicans infections: Pathogenesis, immunity and vaccine prospects. *BJOG: An International Journal of Obstetrics and Gynaecology*, 122(6), 785–794. <https://doi.org/10.1111/1471-0528.12994>
- Cazorla-Luna, R., Martín-Illana, A., Notario-Pérez, F., Miguel Bedoya, L., Tamayo, A., Ruiz-Caro, R., Rubio, J., & Veiga, M. D. (2020). Vaginal polyelectrolyte layer-by-layer films based on chitosan derivatives and Eudragit® S100 for pH responsive release of tenofovir. *Marine Drugs*, 18(1), 1–22. <https://doi.org/10.3390/md18010044>
- Cristiano, M. C., Froiio, F., Mancuso, A., de Gaetano, F., Ventura, C. A., Fresta, M., & Paolino, D. (2020). The Rheolaser Master™ and Kinexus Rotational Rheometer® to Evaluate the Influence of Topical Drug Delivery Systems on Rheological Features of Topical Poloxamer Gel. *Molecules*, 25(8), 1979. <https://doi.org/10.3390/molecules25081979>
- de Beule, K., & Gestel, J. van. (2001). Pharmacology of Itraconazole. In *Drugs* (Vol. 61). <https://doi.org/10.2165/00003495-200161001-00003>
- Dumortier, G., Grossiord, J. L., Agnely, F., & Chaumeil, J. C. (2006). A review of poloxamer 407 pharmaceutical and pharmacological characteristics. In *Pharmaceutical Research* (Vol. 23, Issue 12, pp. 2709–2728). Springer Science and Business Media Deutschland GmbH. <https://doi.org/10.1007/s11095-006-9104-4>
- Dwi Hudiayanti. (2018). *Fosfolipida: Biosurfaktan* (Vol. 1). http://eprints.undip.ac.id/78141/1/fosfolipida_biosurfaktan.pdf
- Emami, L., Faghieh, Z., Ataollahi, E., Sadeghian, S., Rezaei, Z., & Khabnadideh, S. (2023). Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents. *Current Medicinal Chemistry*, 30(2), 220–249. <https://doi.org/10.2174/0929867329666220407094430>
- Eroğlu, İ., Azizoğlu, E., Özyazıcı, M., Nenni, M., Gürer Orhan, H., Özbal, S., Tekmen, I., Ertam, İ., Ünal, İ., & Özer, Ö. (2016). Effective topical delivery systems for corticosteroids: dermatological and histological evaluations. *Drug Delivery*, 23(5), 1502–1513. <https://doi.org/10.3109/10717544.2014.960981>
- European Medicine Agency. (2022). *ICH guideline Q14 on analytical procedure development*. www.ema.europa.eu/contact
- Farr, A., Effendy, I., Frey Tirri, B., Hof, H., Mayser, P., Petricevic, L., Ruhnke, M., Schaller, M., Schaefer, A. P. A., Sustr, V., Willinger, B., & Mendling, W. (2021). Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k). *Mycoses*, 64(6), 583–602. <https://doi.org/10.1111/myc.13248>

- Fenny, S., & Safitri, I. (2021). *Overview: Application of Carbopol 940 in Gel*. <https://doi.org/10.2991/ahsr.k.210127.018>
- Gonçalves, B., Ferreira, C., Alves, C. T., Henriques, M., Azeredo, J., & Silva, S. (2016). Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. *Critical Reviews in Microbiology*, 42(6), 905–927. <https://doi.org/10.3109/1040841X.2015.1091805>
- Grant, S. M., & Clissold, S. P. (1989). Itraconazole. *Drugs*, 37(3), 310–344. <https://doi.org/10.2165/00003495-198937030-00003>
- Graziottin, A., & Gambini, D. (2015). Anatomy and physiology of genital organs - women. In *Handbook of Clinical Neurology* (1st ed., Vol. 130). Elsevier B.V. <https://doi.org/10.1016/b978-0-444-63247-0.00004-3>
- Grimaudo, M. A., Pescina, S., Padula, C., Santi, P., Concheiro, A., Alvarez-Lorenzo, C., & Nicoli, S. (2018). Poloxamer 407/TPGS Mixed Micelles as Promising Carriers for Cyclosporine Ocular Delivery. *Molecular Pharmaceutics*, 15(2), 571–584. <https://doi.org/10.1021/acs.molpharmaceut.7b00939>
- Gupta, A. K., Foley, K. A., & Versteeg, S. G. (2017). New Antifungal Agents and New Formulations Against Dermatophytes. *Mycopathologia*, 182(1–2), 127–141. <https://doi.org/10.1007/s11046-016-0045-0>
- Hecht, H., & Srebnik, S. (2016). Structural Characterization of Sodium Alginate and Calcium Alginate. *Biomacromolecules*, 17(6), 2160–2167. <https://doi.org/10.1021/acs.biomac.6b00378>
- Kathpalia, H., Salunkhe, S., & Juvekar, S. (2019). Formulation of gastroretentive sustained release floating in situ gelling drug delivery system of solubility enhanced curcumin-soy lecithin complex. *Journal of Drug Delivery Science and Technology*, 53. <https://doi.org/10.1016/j.jddst.2019.101205>
- Khan, J., Alexander, A., Ajazuddin, Saraf, S., & Saraf, S. (2013). Recent advances and future prospects of phyto-phospholipid complexation technique for improving pharmacokinetic profile of plant actives. *Journal of Controlled Release*, 168(1), 50–60. <https://doi.org/10.1016/j.jconrel.2013.02.025>
- Kovachev, S. M., & Vatcheva-Dobrevska, R. S. (2015). Local Probiotic Therapy for Vaginal Candida albicans Infections. *Probiotics and Antimicrobial Proteins*, 7(1), 38–44. <https://doi.org/10.1007/s12602-014-9176-0>
- Kumar, M. (2018). Review On Vaginal Drug Delivery System. *Indo American Journal Of Pharmaceutical Research*, 8(11).
- Majeed, A., & Khan, N. A. (2019). Ocular in situ gel: An overview. *Journal of Drug Delivery and Therapeutics*, 9(1), 337–347. <https://doi.org/10.22270/jddt.v9i1.2231>
- Mamuaja, C. F. (2017). *Lipida: Vol. I*. <http://repo.unsrat.ac.id/2031/1/LIPIDA.pdf>
- Martin A, S. J. C. A. (1993). Farmasi fisik : dasar-dasar kimia fisik dalam ilmu farmasetik. In Yoshita (Ed.), *Physical Pharmacy* (2nd ed.). UI-Press.

- Merkus, J. M., & van Heusden, A. M. (1990). Chronic vulvovaginal candidosis: the role of oral treatment. *British Journal of Clinical Practice. Supplement*, 71, 81–84.
- Mirza, M. A., Panda, A. K., Asif, S., Verma, D., Talegaonkar, S., Manzoor, N., Khan, A., Ahmed, F. J., Dudeja, M., & Iqbal, Z. (2016). A vaginal drug delivery model. *Drug Delivery*, 23(8), 3123–3134. <https://doi.org/10.3109/10717544.2016.1153749>
- Mohammed, N. N., Pandey, P., Khan, N. S., Elokely, K. M., Liu, H., Doerksen, R. J., & Repka, M. A. (2016). Clotrimazole–cyclodextrin based approach for the management and treatment of *Candidiasis* – A formulation and chemistry-based evaluation. *Pharmaceutical Development and Technology*, 21(5), 619–629. <https://doi.org/10.3109/10837450.2015.1041041>
- Mohanty, D., Bakshi, V., Simharaju, N., Haque, M. A., & Sahoo, C. (2018). A Review on in situ gel : A Novel Drug Delivery System. *International Journal of Pharmaseutical Sciences Review and Research*.
- Nagasamy Venkatesh, D., Kalyani, K., Tulasi, K., Swetha Priyanka, V., Ali, S. A., & Shashi Kumar, S. (2014). Pharmacosomes: A Potential Vesicular Drug Delivery System. In *International Journal of Pharmaceutical Sciences and Drug Research* (Vol. 6, Issue 2). www.ijpsdr.com
- Nyirjesy, P., & Sobel, J. D. (2003). Vulvovaginal candidiasis. *Obstetrics and Gynecology Clinics of North America*, 30(4), 671–684. [https://doi.org/10.1016/S0889-8545\(03\)00083-4](https://doi.org/10.1016/S0889-8545(03)00083-4)
- Owen, D. H., & Katz, D. F. (1999). A vaginal fluid simulant. *Contraception*, 59(2), 91–95. [https://doi.org/10.1016/S0010-7824\(99\)00010-4](https://doi.org/10.1016/S0010-7824(99)00010-4)
- PERDOSKI. (2017). *Panduan Praktik Klinis*. <https://perdoski.id/uploads/original/2017/10/PPKPERDOSKI2017>
- Permana, A. D., Paredes, A. J., Volpe-Zanutto, F., Anjani, Q. K., Utomo, E., & Donnelly, R. F. (2020). Dissolving microneedle-mediated dermal delivery of itraconazole nanocrystals for improved treatment of cutaneous candidiasis. *European Journal of Pharmaceutics and Biopharmaceutics*, 154, 50–61. <https://doi.org/10.1016/j.ejpb.2020.06.025>
- Piérard, G., Arrese, J., & Piérard-Franchimont, C. (2000). Itraconazole. *Expert Opinion on Pharmacotherapy*, 1(2), 287–304. <https://doi.org/10.1517/14656566.1.2.287>
- Puscaselu, R., Gutt, G., & Amariei, S. (2020). The use of edible films based on sodium alginate in meat product packaging: An eco-friendly alternative to conventional plastic materials. In *Coatings* (Vol. 10, Issue 2). MDPI AG. <https://doi.org/10.3390/coatings10020166>
- Rençber, S., Karavana, S. Y., Şenyiğit, Z. A., Eraç, B., Limoncu, M. H., & Baloğlu, E. (2017). Mucoadhesive in situ gel formulation for vaginal delivery of clotrimazole: formulation, preparation, and in vitro/in vivo evaluation. *Pharmaceutical Development and Technology*, 22(4), 551–561. <https://doi.org/10.3109/10837450.2016.1163385>

- Rossi, R., Basilico, F., Rossoni, G., Riva, A., Morazzoni, P., & Mauri, P. L. (2009). Liquid chromatography/atmospheric pressure chemical ionization ion trap mass spectrometry of bilobalide in plasma and brain of rats after oral administration of its phospholipidic complex. *Journal of Pharmaceutical and Biomedical Analysis*, 50(2), 224–227. <https://doi.org/10.1016/j.jpba.2009.04.026>
- Rowe, R., Sheskey, P., & Owen, S. (2009). *Hand Book of Pharmaceutical Exipients*.
- Sarada, S, F., & K, P. (2011). In-situ gelling system: A review. *Journal of Chemical and Pharmaceutical Research*, 3(6), 217–221.
- Sarah Chairunnisa, P., & Windhu Wardhana, Y. (2016). Karakterisasi Kristal Bahan Padat Aktif Farmasi : Review Characterization Of Solid State Api Crystals : Review. *Farmaka*. <https://jurnal.unpad.ac.id/farmaka/article/view/10576/5108>
- Saski, W., & Shah, S. G. (1965). *Availability of Drugs in the Presence of Surface-Active Agents I Critical Micelle Concentrations of Some Oxyethylene Oxypropylene Polymers*.
- Savjani, K. T., Gajjar, A. K., & Savjani, J. K. (2012). Drug Solubility: Importance and Enhancement Techniques. *ISRN Pharmaceutics*, 2012, 1–10. <https://doi.org/10.5402/2012/195727>
- Semwal, R. B. R., Semwal, R. B. R., & Semwal, D. K. (2018). Mucoadhesive assessment – An encyclopedic review Mucoadhesive assessment – An encyclopedic review. *Current Medical and Drug Research*, 2(August).
- Sobel, J. D. (2007). Vulvovaginal candidosis. *The Lancet*, 369(9577), 1961–1971. [https://doi.org/10.1016/S0140-6736\(07\)60917-9](https://doi.org/10.1016/S0140-6736(07)60917-9)
- Soliman, K. A., Ullah, K., Shah, A., Jones, D. S., & Singh, T. R. R. (2019). Poloxamer-based in situ gelling thermoresponsive systems for ocular drug delivery applications. *Drug Discovery Today*, 24(8), 1575–1586. <https://doi.org/10.1016/j.drudis.2019.05.036>
- Sosa, L., Calpena, A. C., Silva-Abreu, M., Espinoza, L. C., Rincón, M., Bozal, N., Domenech, O., Rodríguez-Lagunas, M. J., & Clares, B. (2019). Thermoreversible Gel-Loaded Amphotericin B for the Treatment of Dermal and Vaginal Candidiasis. *Pharmaceutics*, 11(7), 312. <https://doi.org/10.3390/pharmaceutics11070312>
- Spence, D. (2010). Candidiasis (vulvovaginal). *BMJ Clinical Evidence*, 2010.
- Spinillo, A., Colonna, L., Piazzzi, G., Baltaro, F., Monaco, A., & Ferrari, A. (1997). Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. *The Journal of Reproductive Medicine*, 42(2), 83–87.
- Squier, C. A., Mantz, M. J., Schlievert, P. M., & Davis, C. C. (2008). Porcine vagina ex vivo as a model for studying permeability and pathogenesis in mucosa. *Journal of Pharmaceutical Sciences*, 97(1), 9–21. <https://doi.org/10.1002/jps.21077>
- Srikrishna, S., & Cardozo, L. (2013). The vagina as a route for drug delivery: A review. *International Urogynecology Journal and Pelvic Floor*


- Dysfunction*, 24(4), 537–543. <https://doi.org/10.1007/s00192-012-2009-3>
- Sukartini, T., & Sunarno, A. (2009). *Efektifitas Kombinasi Klorin 0,5% Dan Alkohol 70% Terhadap Pertumbuhan Kuman*. <https://media.neliti.com/media/publications/117676-ID-none.pdf>
- Tang, J., Bao, J., Shi, X., Sheng, X., & Su, W. (2018). Preparation, optimisation, and in vitro–in vivo evaluation of febuxostat ternary solid dispersion. *Journal of Microencapsulation*, 35(5), 454–466. <https://doi.org/10.1080/02652048.2018.1526339>
- Tentor, F., Siccardi, G., Sacco, P., Demarchi, D., Marsich, E., Almdal, K., Bose Goswami, S., & Boisen, A. (2020). Long lasting mucoadhesive membrane based on alginate and chitosan for intravaginal drug delivery. *Journal of Materials Science: Materials in Medicine*, 31(3). <https://doi.org/10.1007/s10856-020-6359-y>
- Thomas, P., Sekhar, A. C., Upreti, R., Mujawar, M. M., & Pasha, S. S. (2015). Optimization of single plate-serial dilution spotting (SP-SDS) with sample anchoring as an assured method for bacterial and yeast cfu enumeration and single colony isolation from diverse samples. In *Biotechnology Reports* (Vol. 8). Elsevier B.V. <https://doi.org/10.1016/j.btre.2015.08.003>
- Tri, *, Kurniawan, B., Bintari, H., Susanti, R., & Biologi, J. (2014). Alamat korespondensi: Gedung D6 Lt 1. Kampus Unnes Jl. Raya sekaran Gunungpati. *Biosaintifika*, 6(2), 50229. <https://doi.org/10.15294/biosaintifika.v6i2.3783>
- Vacheva-Dobrevski, R., Kovachev, S., Nacheva, A., Stoev, S., & Vasilev, N. (2004a). [Comparative study of itraconazole and fluconazole therapy in vaginal candidosis]. *Akusherstvo i Ginekologija*, 43(1), 20–23.
- Vacheva-Dobrevski, R., Kovachev, S., Nacheva, A., Stoev, S., & Vasilev, N. (2004b). [Comparative study of itraconazole and fluconazole therapy in vaginal candidosis]. *Akusherstvo i Ginekologija*, 43(1), 20–23.
- van Hoogevest, P. (2017). Review – An update on the use of oral phospholipid excipients. *European Journal of Pharmaceutical Sciences*, 108, 1–12. <https://doi.org/10.1016/j.ejps.2017.07.008>
- Wang, L., & Liu, X. (2019). Sustained release technology and its application in environmental remediation: A review. *International Journal of Environmental Research and Public Health*, 16(12). <https://doi.org/10.3390/ijerph16122153>
- WHO. (2009). *Laboratory Manual For Diagnosis of Fungal opportunistic infections in HIV/AIDS patients*.
- Willems, H. M. E., Ahmed, S. S., Liu, J., Xu, Z., & Peters, B. M. (2020). Vulvovaginal candidiasis: A current understanding and burning questions. In *Journal of Fungi* (Vol. 6, Issue 1). MDPI AG. <https://doi.org/10.3390/jof6010027>
- Wirantari, N., & Hidayati, A. N. (2008). *Peran Lactobacillus Pada Managemen Infeksi Endogen Genitalia Wanita The Role Of*

Lactobacillus In Managing Endogenous Female Genital Tract Infections. <https://doi.org/10.33820/mdvi.v45i2.22>

Zhu, Z., Zhai, Y., Zhang, N., Leng, D., & Ding, P. (2013). The development of polycarbophil as a bioadhesive material in pharmacy. *Asian Journal of Pharmaceutical Sciences*, 8(4), 218–227. <https://doi.org/10.1016/j.ajps.2013.09.003>

LAMPIRAN

Lampiran 1. Panjang Gelombang Maksimum Itraconazole




Gambar 20. Grafik panjang gelombang maksimum itraconazole dalam methanol dan cairan vagina buatan

Lampiran 2. Kurva Baku Itraconazole



Gambar 21 : Kurva baku itraconazole dalam cairan buatan vagina



Gambar 22 : Kurva baku itraconazole dalam methanol

Lampiran 3. Hasil uji optimasi LK-ITR

Tabel 10 : Hasil Optimasi Kelarutan LK-ITR Dalam Cairan Vagina Buatan

Formula	Replikasi	y	b	a	$\mu\text{g/mL}$	Faktor Pengenceran	mg/mL	Rata-rata \pm SD
ITR murni	1	0,478	0,0488	0,0045	9,703	97,03	0,097	96.141 \pm 2,28
	2	0,461	0,0488	0,0045	9,355	93,55	0,094	
	3	0,482	0,0488	0,0045	9,785	97,85	0,098	
F1	1	0,219	0,0488	0,0045	4,395	439,55	0,440	442,96 \pm 3,13
	2	0,221	0,0488	0,0045	4,436	443,65	0,444	
	3	0,222	0,0488	0,0045	4,457	445,70	0,446	
F2	1	0,260	0,0488	0,0045	5,236	523,57	0,524	527,66 \pm 4,09
	2	0,262	0,0488	0,0045	5,277	527,66	0,528	
	3	0,264	0,0488	0,0045	5,318	531,76	0,532	
F3	1	0,360	0,0488	0,0045	7,285	728,48	0,728	735,31 \pm 6,26
	2	0,364	0,0488	0,0045	7,367	736,68	0,737	
	3	0,366	0,0488	0,0045	7,408	740,78	0,741	
F4	1	0,410	0,0488	0,0045	8,309	830,94	0,831	839,13 \pm 12,46
	2	0,421	0,0488	0,0045	8,535	853,48	0,853	
	3	0,411	0,0488	0,0045	8,330	832,99	0,833	
F5	1	0,631	0,0488	0,0045	12,838	1283,8	1,284	1.275,61 \pm 10,84
	2	0,621	0,0488	0,0045	12,633	1263,3	1,263	
	3	0,629	0,0488	0,0045	12,797	1279,7	1,280	

Tabel 11 : Hasil Optimasi Kelarutan LK-ITR Dalam Air

Formula	Replikasi	y	b	a	$\mu\text{g/mL}$	Faktor Pengenceran	mg/mL	Rata-rata \pm SD
ITZ murni	1	0,275	0,0488	0,0045	5,543	55,43	0,055	57,07 \pm 2,02
	2	0,280	0,0488	0,0045	5,645	56,45	0,056	
	3	0,294	0,0488	0,0045	5,932	59,32	0,059	
F1	1	0,104	0,0488	0,0045	2,046	204,58	0,205	205,03 \pm 1,42
	2	0,104	0,0488	0,0045	2,039	203,89	0,204	
	3	0,105	0,0488	0,0045	2,066	206,63	0,207	
F2	1	0,194	0,0488	0,0045	3,890	389,00	0,389	391,05 \pm 2,05
	2	0,195	0,0488	0,0045	3,911	391,05	0,391	
	3	0,196	0,0488	0,0045	3,931	393,10	0,393	
F3	1	0,216	0,0488	0,0045	4,334	433,40	0,433	435,45 \pm 2,46
	2	0,217	0,0488	0,0045	4,348	434,77	0,435	
	3	0,218	0,0488	0,0045	4,382	438,18	0,438	
F4	1	0,327	0,0488	0,0045	6,609	660,86	0,661	642,65 \pm 19,59
	2	0,319	0,0488	0,0045	6,452	645,15	0,645	
	3	0,308	0,0488	0,0045	6,219	621,93	0,622	
F5	1	0,420	0,0488	0,0045	8,521	852,1	0,852	854,17 \pm 9,39
	2	0,426	0,0488	0,0045	8,644	864,4	0,864	
	3	0,417	0,0488	0,0045	8,460	846,0	0,846	

*F1,F2,F3,F4 dan F5 adalah kode untuk formula LK-ITR

Lampiran 4. Hasil uji aktifitas antifungi

Tabel 12. Hasil uji diameter zona hambat

Replikasi	Diameter Zona Hambatan (mm)			
	A*	B	C	D
1	0	26,1	21,3	19,8
2	0	25,9	21,6	19,5
3	0	26,2	21,5	19,3
Rata-Rata	0	26,07	21,47	19,53
SD	0	0,15	0,15	0,25

*A : P90G

B : LK-ITR

C : Campuran fisik P90G-ITR

D : ITR murni

Tabel 13. Perhitungan jumlah koloni

a. Jumlah koloni perlakuan jam ke 0

Jumlah Koloni Tiap Pengenceran												Jumlah Koloni	Log CFU/mL	Populasi <i>C.albicans</i> (%)
Replikasi 1						Replikasi 2								
10 ⁻⁶	10 ⁻⁷	10 ⁻⁸	10 ⁻⁹	10 ⁻¹⁰	10 ⁻¹¹	10 ⁻⁶	10 ⁻⁷	10 ⁻⁸	10 ⁻⁹	10 ⁻¹⁰	10 ⁻¹¹			
TBUD	TBUD	536	292	136	-	TBUD	TBUD	552	268	168	-	1,4 x10 ⁻¹²	12,13	100,00%

b. Jumlah koloni perlakuan jam ke 1

Kelompok	Jumlah Koloni Tiap Pengenceran												Jumlah Koloni	Log CFU/mL	Populasi <i>C.albicans</i> (%)
	Replikasi 1						Replikasi 2								
	10 ⁻⁶	10 ⁻⁷	10 ⁻⁸	10 ⁻⁹	10 ⁻¹⁰	10 ⁻¹¹	10 ⁻⁶	10 ⁻⁷	10 ⁻⁸	10 ⁻⁹	10 ⁻¹⁰	10 ⁻¹¹			
Gel ITR murni	TBUD	392	246	132	-	-	TBUD	TBUD	348	192	108	-	1,2x10 ⁻¹¹	11,08	91,31%
Formula G1	TBUD	361	246	114	-	-	TBUD	TBUD	311	238	124	-	1, 2x10 ⁻¹¹	11,08	91,28%
Formula G2	TBUD	357	229	109	-	-	TBUD	TBUD	336	242	118	-	1,12x10 ⁻¹¹	11,05	91,11%
Formula G3	TBUD	356	224	92	-	-	TBUD	TBUD	348	208	86	-	8,9x10 ⁻¹⁰	10,95	90,24%
<i>Untreated</i>	TBUD	TBUD	394	292	146	-	TBUD	TBUD	TBUD	336	172	-	1,62x10 ⁻¹²	12,20	100,56%

* TBUD : Tidak Bisa Untuk Dihitung

c. Jumlah koloni perlakuan jam ke 4

Formula	Jumlah Koloni Tiap Pengenceran												Jumlah Koloni	Log CFU/mL	Populasi <i>C.albicans</i> (%)
	Replikasi 1						Replikasi 2								
	10 ⁻⁶	10 ⁻⁷	10 ⁻⁸	10 ⁻⁹	10 ⁻¹⁰	10 ⁻¹¹	10 ⁻⁶	10 ⁻⁷	10 ⁻⁸	10 ⁻⁹	10 ⁻¹⁰	10 ⁻¹¹			
Gel ITR murni	349	268	146	-	-	-	328	277	149	-	-	-	1,5x10 ⁻¹⁰	10,17	83,81%
Formula G1	326	227	116	-	-	-	342	261	138	-	-	-	1,3 x10 ⁻¹⁰	10,10	83,27%
Formula G2	316	204	98	-	-	-	338	196	112	-	-	-	1,1 x10 ⁻¹⁰	10,02	82,59%
Formula G3	298	195	76	-	-	-	268	182	98	-	-	-	8,7 x10 ⁻⁹	9,94	81,92%
<i>Untreated</i>	TBUD	TBUD	TBUD	392	218	37	TBUD	TBUD	TBUD	425	287	49	4,3 x10 ⁻¹²	12,63	104,12%

d. Jumlah koloni perlakuan jam ke 8

Formula	Jumlah Koloni Tiap Pengenceran												Jumlah Koloni	Log CFU/mL	Populasi <i>C.albicans</i> (%)
	Replikasi 1						Replikasi 2								
	10 ⁻⁶	10 ⁻⁷	10 ⁻⁸	10 ⁻⁹	10 ⁻¹⁰	10 ⁻¹¹	10 ⁻⁶	10 ⁻⁷	10 ⁻⁸	10 ⁻⁹	10 ⁻¹⁰	10 ⁻¹¹			
Gel ITR murni	287	194	92	-	-	-	268	163	71	-	-	-	8,2 x10 ⁻⁹	9,91	81,68%
Formula G1	226	152	81	-	-	-	211	158	69	-	-	-	7,5 x10 ⁻⁹	9,88	81,39%
Formula G2	219	159	74	-	-	-	197	142	56	-	-	-	6,5 x10 ⁻⁹	9,81	80,87%
Formula G3	182	107	28	-	-	-	163	93	31	-	-	-	3,0 x10 ⁻⁹	9,47	74,17%
<i>Untreated</i>	TBUD	TBUD	TBUD	268	173	89	TBUD	TBUD	TBUD	254	166	73	8,1 x10 ⁻¹²	12,91	106,39%

* TBUD : Tidak Bisa Untuk Dihitung

e. Jumlah koloni perlakuan jam ke 24

Formula	Jumlah Koloni Tiap Pengenceran												Jumlah Koloni	Log CFU/mL	Populasi <i>C.albicans</i> (%)
	Replikasi 1						Replikasi 2								
	10 ⁻²	10 ⁻³	10 ⁻⁴	10 ⁻⁵	10 ⁻⁶	10 ⁻⁷	10 ⁻²	10 ⁻³	10 ⁻⁴	10 ⁻⁵	10 ⁻⁶	10 ⁻⁷			
Gel ITR murni	TBUD	314	269	183	75	-	TBUD	349	273	162	64	-	7,0x10 ⁻⁷	7,84	64,63%
Formula G1	198	69	10	-	-	-	183	66	13	-	-	-	6,810 ⁻⁴	4,83	39,80%
Formula G2	187	57	11	-	-	-	179	44	9	-	-	-	5,1x10 ⁻⁴	4,70	38,76%
Formula G3	64	21	6	-	-	-	68	24	7	-	-	-	6,7x10 ⁻³	3,82	31,48%
<i>Untreated</i>	TBUD	TBUD	TBUD	TBUD	TBUD	TBUD	TBUD	TBUD	TBUD	TBUD	TBUD	TBUD			

Formula	Jumlah Koloni Tiap Pengenceran												Jumlah Koloni	Log CFU/mL	Populasi <i>C.albicans</i> (%)	
	Replikasi 1						Replikasi 2									
	10 ⁻⁸	10 ⁻⁹	10 ⁻¹⁰	10 ⁻¹¹	10 ⁻¹²	10 ⁻¹³	10 ⁻⁸	10 ⁻⁹	10 ⁻¹⁰	10 ⁻¹¹	10 ⁻¹²	10 ⁻¹³				
Gel ITR murni	-	-	-	-	-	-	-	-	-	-	-	-	-	7,0x10 ⁻⁷	7,84	64,63%
Formula G1	-	-	-	-	-	-	-	-	-	-	-	-	-	6,810 ⁻⁴	4,83	39,80%
Formula G2	-	-	-	-	-	-	-	-	-	-	-	-	-	5,1x10 ⁻⁴	4,70	38,76%
Formula G3	-	-	-	-	-	-	-	-	-	-	-	-	-	6,7x10 ⁻³	3,82	31,48%
<i>Untreated</i>	TBUD	TBUD	316	195	73	-	TBUD	TBUD	388	207	69	-	7,1 x10 ⁻¹³	13,85	114,16%	

* TBUD : Tidak Bisa Untuk Dihitung

f. Cara perhitungan jumlah koloni

1. Cawan yang dipilih dan dihitung adalah yang mengandung koloni antara 15-150
2. Angka yang ditulis sebagai jumlah koloni adalah 2 angka yaitu 1 angka didepan koma dan 1 angka dibelakang koma. Setiap angka dikalikan dengan faktor pengencerannya.
3. Jumlah koloni yang diperoleh dimasukkan kedalam rumus

$$\text{Jumlah koloni} = \text{Jumlah koloni} \times \frac{1}{FP}$$

FP : Faktor pengenceran

Contoh :

Jumlah koloni pengamatan :

FP 10^{-3} : 53

Jumlah koloni = $53 \times 1/10^{-3}$

$$= 53 \times 10^3$$

$$= 5,3 \times 10^4$$

Lampiran 5. Hasil uji permeasi

Tabel 14. Hasil permeasi gel
a. Formula G1

Jam	Replikasi	y	x (µg/ml)	FP	µg/1,5 ml	µg /28 ml	Faktor Koreksi	Jumlah Terpermeasi (mg)	Rata-rata	SD
0,5	1	0,000				0	0,00	0	0,00	0,00
	2	0,000				0	0,00	0		
	3	0,000				0	0,00	0		
1	1	0,119	2,346		3,519	0,066	0,00	0,066	0,06	0,00
	2	0,105	2,059		3,089	0,058	0,00	0,058		
	3	0,108	2,121		3,181	0,059	0,00	0,059		
2	1	0,212	4,252		6,378	0,119	0,12	0,238	0,25	0,01
	2	0,229	4,600		6,901	0,129	0,13	0,258		
	3	0,234	4,703		7,054	0,132	0,13	0,263		
3	1	0,299	6,035		9,052	0,169	0,29	0,457	0,48	0,02
	2	0,322	6,506		9,759	0,182	0,31	0,493		
	3	0,319	6,445		9,667	0,180	0,31	0,493		
4	1	0,365	7,387		11,081	0,207	0,49	0,702	0,71	0,01
	2	0,352	7,121		10,681	0,199	0,51	0,710		
	3	0,361	7,305		10,958	0,205	0,52	0,721		

5	1	0,388	7,859		11,788	0,220	0,71	0,935	0,95	0,02
	2	0,383	7,756		11,634	0,217	0,73	0,945		
	3	0,397	8,043		12,065	0,225	0,74	0,967		
6	1	0,414	8,391		12,587	0,235	0,95	1,185	1,19	0,01
	2	0,416	8,432		12,649	0,236	0,96	1,200		
	3	0,404	8,186		12,280	0,229	0,97	1,200		
7	1	0,518	10,523		15,784	0,295	1,24	1,539	1,54	0,01
	2	0,497	10,092		15,138	0,283	1,25	1,529		
	3	0,499	10,133		15,200	0,284	1,25	1,539		
8	1	0,506	10,277		15,415	0,288	1,53	1,820	1,83	0,01
	2	0,512	10,400		15,599	0,291	1,54	1,829		
	3	0,522	10,605		15,907	0,297	1,55	1,849		
24	1	0,126	2,490	24,898	3,735	0,697	2,23	2,927	2,97	0,04
	2	0,132	2,613	26,127	3,919	0,732	2,27	3,001		
	3	0,128	2,531	25,307	3,796	0,709	2,26	2,969		

b. Hasil permeasi formula G2

Jam	Replikasi	y	x ($\mu\text{g/ml}$)	FP	$\mu\text{g}/1,5$ ml	$\mu\text{g} /28$ ml	Faktor Koreksi	Jumlah Terpermeasi (mg)	Rata-rata	SD
0,5	1	0,000	0			71,434	0,00	0,00	0,00	0,00
	2	0,000	0			64,549	0,00	0,00		
	3	0,000	0			69,713	0,00	0,00		
1	1	0,129	2,551		3,827	147,746	0,00	0,07	0,07	0,00
	2	0,117	2,305		3,458	142,582	0,00	0,06		
	3	0,126	2,490		3,735	150,041	0,00	0,07		
2	1	0,262	5,277		7,915	167,828	0,07	0,22	0,22	0,01
	2	0,253	5,092		7,638	162,664	0,06	0,21		
	3	0,266	5,359		8,038	191,352	0,07	0,22		
3	1	0,297	5,994		8,991	184,467	0,22	0,39	0,39	0,02
	2	0,288	5,809		8,714	176,434	0,21	0,37		
	3	0,338	6,834		10,251	224,631	0,22	0,41		
4	1	0,326	6,588		9,882	216,025	0,39	0,57	0,58	0,05
	2	0,312	6,301		9,452	224,631	0,37	0,55		
	3	0,396	8,023		12,034	242,992	0,41	0,64		
5	1	0,381	7,715		11,573	264,795	0,57	0,79	0,81	0,06
	2	0,396	8,023		12,034	280,287	0,55	0,77		
	3	0,428	8,678		13,017	279,139	0,64	0,88		

6	1	0,466	9,457		14,185	331,352	0,79	1,05	1,09	0,06
	2	0,493	10,010		15,015	347,992	0,77	1,05		
	3	0,491	9,969		14,954	377,828	0,88	1,16		
7	1	0,582	11,834		17,751	361,189	1,05	1,38	1,44	0,08
	2	0,611	12,428		18,642	363,484	1,05	1,40		
	3	0,663	13,494		20,241	360,041	1,16	1,54		
8	1	0,634	12,900		19,349	645,492	1,38	1,74	1,80	0,08
	2	0,638	12,982		19,472	685,656	1,40	1,76		
	3	0,632	12,859		19,288	1098,770	1,54	1,90		
24	1	0,117	2,305	23,053	34,580	71,434	1,74	2,39	2,61	0,33
	2	0,124	2,449	24,488	36,732	64,549	1,76	2,45		
	3	0,196	3,924	39,242	58,863	69,713	1,90	2,99		

c. Hasil permeasi formula G3

Jam	Replikasi	y	x ($\mu\text{g/ml}$)	F P	$\mu\text{g/1,5 ml}$	mg/28 ml	Faktor Koreksi	Jumlah Terpermeasi (mg)	Rata-rata	SD
0,5	1	0,000					0,00	0	0,00	0,00
	2	0,000					0,00	0		
	3	0,000					0,00	0		
1	1	0,177	3,535		5,302	0,148	0,00	0,148	0,15	0,00
	2	0,183	3,658		5,487	0,154	0,00	0,154		
	3	0,172	3,432		5,149	0,144	0,00	0,144		
2	1	0,186	3,719		5,579	0,156	0,16	0,312	0,31	0,00
	2	0,188	3,760		5,640	0,158	0,16	0,316		
	3	0,184	3,678		5,517	0,154	0,15	0,309		
3	1	0,189	3,781		5,671	0,159	0,32	0,474	0,48	0,00
	2	0,192	3,842		5,763	0,161	0,32	0,481		
	3	0,192	3,842		5,763	0,161	0,32	0,477		
4	1	0,204	4,088		6,132	0,172	0,49	0,658	0,65	0,00
	2	0,199	3,986		5,978	0,167	0,49	0,654		
	3	0,199	3,986		5,978	0,167	0,48	0,651		
5	1	0,213	4,273		6,409	0,179	0,67	0,846	0,86	0,03
	2	0,213	4,273		6,409	0,179	0,67	0,846		
	3	0,246	4,951		7,427	0,208	0,69	0,899		

6	1	0,264	5,322	7,983	0,224	0,89	1,113	1,11	0,01
	2	0,257	5,164	7,746	0,217	0,88	1,100		
	3	0,256	5,143	7,715	0,216	0,91	1,123		
7	1	0,213	4,275	6,412	0,180	1,07	1,249	1,22	0,02
	2	0,192	3,838	5,758	0,161	1,04	1,205		
	3	0,185	3,689	5,534	0,155	1,06	1,217		
8	1	0,199	3,983	5,974	0,167	1,24	1,404	1,43	0,03
	2	0,239	4,812	7,218	0,202	1,25	1,448		
	3	0,229	4,600	6,900	0,193	1,26	1,449		
24	1	0,392	7,941	11,911	0,334	1,57	1,903	1,91	0,01
	2	0,394	7,982	11,972	0,335	1,58	1,917		
	3	0,392	7,941	11,911	0,334	1,59	1,922		

d. Cara perhitungan uji permeasi pada vagina

Hasil serapan yang terbaca pada alat spektrofotometri UV Vis dimasukkan kedalam persamaan regresi sebagai berikut :

$$y = 0,0488x + 0,0045 \quad (R^2 = 0,9955)$$

y : serapan

x : kadar ($\mu\text{g/mL}$)

Contoh :

Pada cuplikan sampel jam ke 1 didapatkan serapan 0,177

$$\begin{aligned} x &= \frac{0,177 - 0,0045}{0,0488} \\ &= \frac{0,1725}{0,0488} \\ &= 3,535 \mu\text{g/mL} \end{aligned}$$

$$\text{Kadar dalam 1,5 mL} = \frac{3,535 \times 1,5}{1000} = 0,0053 \text{ mg}$$

$$\text{Kadar dalam 28 mL} = 0,0053 \times 28 = 0,148 \text{ mg}$$

Jumlah yang terpermeasi = Kadar dalam 28 mL + Faktor Koreksi

Menentukan faktor koreksi :

$$\frac{\text{Kadar sebelumnya}}{1000} \times \text{Faktor koreksi jam sebelumnya}$$

Faktor koreksi jam sebelumnya 0 mg sebab tidak ada serapan pada cuplikan ke jam 0,5.

Jumlah terpermeasi = Kadar dalam 28 mL + faktor koreksi

$$= 0,148 \text{ mg} + 0$$

$$= 0,148 \text{ mg}$$

Lampiran 6. Hasil uji retensi gel

Tabel 15. Hasil permeasi gel

Formula*	Replikasi	y	x (µg/ml)	FP	mg yang terdeposisi	Rata-rata	SD	% Retain
G1	1	0,376	3,944	100	3,94	3,99	0,07	39,92%
	2	0,377	3,962	100	3,96			
	3	0,383	4,071	100	4,07			
G2	1	0,390	4,199	100	4,20	4,16	0,16	41,56%
	2	0,378	3,980	100	3,98			
	3	0,395	4,290	100	4,29			
G3	1	0,421	4,763	100	4,76	4,72	0,06	47,21%
	2	0,420	4,745	100	4,74			
	3	0,415	4,654	100	4,65			
Kontrol	1	0,218	1,066	100	1,07	1,14	0,07	11,45%
	2	0,223	1,157	100	1,16			
	3	0,226	1,211	100	1,21			

*G1,G2,G3 adalah nama formula gel

Tabel 16. Hasil uji persen obat kembali


Replikasi	Formula	Abs	Konsentrasi (ug/mL)	Faktor Pengenceran 100	Konsentrasi mg/mL	mg/10ml	% Obat Kembali	Rata-rata	SD
1	G1	0,486	9,867	986,680	0,987	9,87	98,67%	98,94%	0,24%
2		0,488	9,908	990,779	0,991	9,91	99,08%		
3		0,488	9,908	990,779	0,991	9,91	99,08%		
1	G2	0,489	9,928	992,828	0,993	9,93	99,28%	99,21%	0,12%
2		0,489	9,928	992,828	0,993	9,93	99,28%		
3		0,488	9,908	990,779	0,991	9,91	99,08%		
1	G3	0,488	9,900	989,959	0,990	9,90	99,00%	98,85%	0,17%
2		0,486	9,867	986,680	0,987	9,87	98,67%		
3		0,487	9,887	988,730	0,989	9,89	98,87%		

Tabel 17. Hasil uji viskositas

Replikasi	Formula	Suhu (°C)								
		4			25			37		
		Viskositas	Rata-rata	SD	Viskositas	Rata-rata	SD	Viskositas	Rata-rata	SD
1	G1	226	232,0	5,29	2123	2115,3	18,72	31548	31550,7	4,62
2		234			2129			31548		
3		236			2094			31556		
1	G2	277	279,3	2,08	2836	2835,0	9,54	36215	36225,7	15,95
2		280			2825			36218		
3		281			2844			36244		
1	G3	285	312,0	23,39	3327	3333,0	5,20	39918	39916,7	1,15
2		325			3336			39916		
3		326			3336			39916		
1	Kontrol	297	294,0	5,20	3419	3420,0	1,73	38234	38249,3	13,32
2		297			3419			38256		
3		288			3422			38258		

Lampiran 7. Spektroskopi FT-IR

a. Spektroskopi FT-IR Itraconazol



	Peak	Intensity	Corr. Intensity	Base (H)	Base (L)	Area	Corr. Area
1	362,62	60,867	36,113	435,91	343,33	8,259	7,426
2	453,27	99,058	0,657	472,56	437,84	0,1	0,056
3	505,35	98,569	1,48	524,64	484,13	0,122	0,131
4	580,57	98,998	1,058	609,51	557,43	0,106	0,117
5	680,23	97,002	1,585	688,59	628,79	0,38	0,113
6	719,45	96,429	2,66	748,38	688,59	0,614	0,366
7	765,74	98,908	1,036	783,1	748,38	0,089	0,081
8	809,68	96,066	3,897	846,75	783,1	0,5	0,483
9	918,12	98,509	1,291	929,69	896,9	0,139	0,1
10	968,27	88,467	11,448	995,27	931,62	1,496	1,473
11	1010,7	99,149	0,767	1022,27	995,27	0,058	0,048
12	1056,99	84,424	4,875	1068,56	1024,2	2,102	0,656
13	1087,85	81,253	9,16	1122,57	1070,49	2,768	0,978
14	1189,36	89,962	1,363	1190,08	1124,5	1,767	0,346
15	1216,58	77,474	15,982	1305,81	1192,01	5,985	3,39
16	1336,67	98,949	0,768	1352,1	1307,74	0,125	0,078
17	1377,17	96,584	3,218	1402,25	1352,1	0,382	0,339
18	1462,04	87,72	9,753	1496,76	1404,18	2,466	1,649
19	1512,19	93,297	4,299	1533,41	1496,76	0,679	0,337
20	1548,84	97,178	2,56	1566,2	1533,41	0,226	0,188
21	1645,28	96,908	2,849	1666,5	1597,06	0,508	0,436


22	1681,29	88,837	2,41	1707	1666,5	1,107	0,084
23	1734,01	73,451	20,527	1766,8	1707	4,526	2,969
24	1840,09	99,629	0,267	1851,66	1811,16	0,036	0,026
25	1913,39	99,446	0,213	1932,67	1901,81	0,056	0,014
26	2140,99	99,656	0,158	2241,28	2094,69	0,169	0,057
27	2561,47	99,73	0,062	2592,33	2532,54	0,062	0,007
28	2742,78	99,272	0,618	2771,71	2698,41	0,105	0,064
29	2852,72	74,911	16,037	2875,86	2773,64	4,213	1,783
30	2922,16	62,53	30,585	2987,74	2877,79	10,088	7,114
31	3008,95	94,196	5,834	3034,03	2987,74	0,52	0,525
32	3066,82	99,85	0,145	3078,39	3049,46	0,008	0,009
33	3414	79,333	20,711	3657,04	3080,32	32,575	32,654

Date/Time; 11/11/2022 4:19:56

PM

No. of Scans;

b. Spektroskopi FT-IR Itraconazol

	Peak	Intensity	Corr. Intensity	Base (H)	Base (L)	Area	Corr. Area
1	372,26	75,23	24,51	459,06	343,33	7,71	7,62
2	474,49	95,14	4,91	493,78	459,06	0,39	0,4
3	507,28	97,71	2,27	526,57	493,78	0,19	0,19
4	549,71	81,09	18,35	567,07	528,5	1,72	1,63
5	680,66	98,12	1,6	682,8	636,51	0,21	0,15
6	709,8	97,09	2	721,38	696,3	0,23	0,12
7	761,88	86,13	13,33	783,1	723,31	1,71	1,56
8	809,89	72,7	17,62	860,25	827,46	3,03	1,52
9	875,68	91,2	8,49	896,9	862,18	0,69	0,64
10	968,27	76,84	22,84	1001,06	941,26	2,78	2,69
11	1033,85	93,58	5,76	1056,99	1001,06	0,81	0,65
12	1189,57	91,27	8,89	1163,08	1134,14	0,58	0,6
13	1216,51	82,46	11,46	1228,66	1190,08	2,03	1,1
14	1249,87	86,28	13,91	1282,66	1230,58	1,61	1,66
15	1338,6	67,55	28,78	1365,6	1317,38	4,11	3,37
16	1390,68	85,32	14,57	1413,82	1367,53	1,64	1,62
17	1436,97	87,7	12,22	1462,04	1415,75	1,23	1,22
18	1512,55	50,88	22,41	1516,05	1465,9	7,44	2,85
19	1537,27	29,09	46,52	1575,84	1517,98	15,42	9,52
20	1595,13	41,95	58,04	1610,56	1577,77	5,89	5,88
21	1681,07	20,98	26,53	1695,43	1637,56	17,46	4,52
22	1741,72	96,46	0,47	1766,8	1737,86	0,28	0,04
23	1928,82	97,38	2,45	1961,61	1884,45	0,43	0,39
24	2052,26	98,42	1,17	2108,2	2031,04	0,21	0,1
25	2218,14	54,1	46,03	2245,14	2191,13	5,36	5,39
26	2601,97	97,32	2,21	2659,84	2569,18	0,56	0,39

27	2735,06	96,47	2,98	2758,21	2696,48	0,47	0,33
28	2852,72	88	11,73	2883,58	2785,21	2,54	2,44
29	2958,8	77,36	14,97	3001,24	2885,51	6,98	3,79
30	3049,46	68,97	14,3	3088,03	3003,17	10,17	3,59
31	3226,91	93,14	6,55	3250,05	3203,76	0,72	0,66
32	3271,27	94,78	4,46	3304,06	3253,91	0,72	0,5
33	3481,51	90,48	0,22	3495,01	3466,08	1,24	0,02

Date/Time; 11/11/2022 4:19:56

PM

No. of Scans;

Lampiran 8 : Dokumentasi penelitian



c. Dokumentasi proses penguapan LK-ITR



d. Dokumentasi penentuan suhu gelas



e. Penentuan viskositas





e. Dokumentasi penyiapan evaluasi ex vivo



f. Penentuan kekuatan mukoadhesif



g. Dokumentasi uji permease



h. Dokumentasi proses kultur *C. albicans* secara ex vivo

